A Phase I, Multicenter, Dose Finding and Dose Confirmation Study to Investigate the Pharmacokinetics, and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy (ARTEMIDE-subQ)

Study Identifier:
D702EC00001
CT.gov Identifier:
NCT07161414
EudraCT Identifier:
202552000000
EU Trial (CTIS) Number:
2025-521614-26-00
Study Contact Information:
N/A
Recruiting

Considering participating in a START clinical trial?

Get Started

Study Summary

The purpose of this study is to determine the subcutaneous (SC) dose that gives rilvegostomig exposure comparable to the intravenous (IV) exposure, and to evaluate the pharmacokinetics (PK) and safety of SC rilvegostomig in adult participants with advanced solid tumors previously treated with standard of care therapy for whom immunooncology (IO) monotherapy would be deemed appropriate by the investigator.

Medical Condition
The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.
  • Solid Tumor
    • Phase
    The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
    I
    Sex
    Female & Male
    Age
    18+ years
    Study Drug
  • Drug: EXPERIMENTAL: Part 1 (dose finding): Cohort A - SC Rilvegostomig Dose Level 1 (DL1) and rHu
    • Read More
  • Drug: Participants will receive IV rilvegostomig (Dose X) as their first dose of study treatment, followed by subsequent treatments with recombinant human hyaluronidase (rHu) and SC rilvegostomig (DL1) at predefined intervals.
  • Drug: Drug: IV Rilvegostomig
  • Drug: Rilvegostomig administered IV.
  • Drug: Other Names: AZD2936
  • Drug: Drug: Recombinant Human Hyaluronidase (rHu)
  • Drug: rHu administered subcutaneously.
  • Drug: Drug: SC Rilvegostomig
  • Drug: Rilvegostomig administered subcutaneously.
  • Drug: EXPERIMENTAL: Part 1 (dose finding): Cohort B - SC Rilvegostomig DL2 and rHu
  • Drug: Participants will receive IV rilvegostomig (Dose X) as their first dose of study treatment, followed by subsequent treatments with rHu and SC rilvegostomig (DL2) at predefined intervals.
  • Drug: EXPERIMENTAL: Part 2 (dose confirmation): SC Rilvegostomig and rHu
  • Drug: Participants will receive SC rilvegostomig and rHu.
  • Drug: Drug: SC rilvegostomig + rHu
  • Drug: SC rilvegostomig + rHu administered subcutaneously.
    • Study Status
    Indicates the current recruitment status or the expanded access status
    Recruiting

    Requirements information
    Inclusion criteria
    • * Histologically or cytologically documented advanced (metastatic and/or unresectable) solid tumor.
    • * Participants must have received prior anticancer treatment for the disease under study.
    • * IO monotherapy deemed appropriate by the investigator.
    • * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment with no deterioration.
    • * Minimum life expectancy of ≥ 12 weeks at enrollment.
    • * Adequate organ and marrow function.
    • * Body weight ≥ 30 kg.
    Exclusion criteria
    • Any severe or uncontrolled systemic diseases, which makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol.
    • * History of organ transplant.
    • * History of another primary malignancy that was active within past 2 years.
    • * Persistent toxicities caused by previous anticancer treatment(s) excluding alopecia, not yet improved to Grade ≤ 1 or baseline.
    • * Unstable, symptomatic brain metastasis or spinal cord compression.
    • * History of leptomeningeal carcinomatosis.
    • * Active primary immunodeficiency/active infectious disease including tuberculosis (TB), human immunodeficiency virus (HIV) infection or hepatitis A, B or C infection.
    • * History of clinically significant arrhythmia, cardiomyopathy of any etiology; symptomatic congestive heart failure, history of myocardial infarction within the past 6 months.
    • * Uncontrolled intercurrent illness including but not limited to ongoing or active known infection; interstitial lung disease (ILD), serious chronic gastrointestinal conditions associated with diarrhea; active non-infectious skin disease requiring systemic treatment.
    • * Active or prior documented autoimmune or inflammatory disorders requiring chronic treatment with steroids or other immunosuppressive treatment.
    • * Known allergy or hypersensitivity to rilvegostomig, hyaluronidase, or any excipients of the investigational products.
    • * Participants experienced a toxicity to prior immunotherapy that led to permanent discontinuation of prior immunotherapy.
    • * Prior anticancer treatment, including immunotherapy, up to 28 days prior to the first dose of study treatment.

    Clinical Study Information for Healthcare Providers

    By clicking the button below you will find in-depth information about this clinical trial, including study design, primary and secondary endpoints, and more. This information is intended for healthcare professionals seeking to review the scientific and operational aspects of the study.

    View Study Information

    Study Locations

    Location
    Investigator
    Status
    Condition(s) Treated at Site
    Location
    START Madrid, Spain (FJD)
    Madrid, Spain, 28040
    Investigator
    Victor Moreno Garcia
    Status
    Recruiting
    Condition(s) Treated at Site
    Solid Tumor